- Raffles Medical continues to explore new growth opportunities in the region amidst structural growth headwinds in Singapore. We see the commitment to pay at least 50% of earnings as dividends and to buy back 100m shares over the next two years as positives.
- - Read this at SGinvestors.io -
- Raffles Medical’s below-peer valuation seems justified by below-peer-average margin and ROE.
Raffles Medical's 2024 results.
- Raffles Medical's 2024 core PATMI was 6% below our estimate amidst higher costs.
- - Read this at SGinvestors.io -
- policy to pay at least 50% of annual earnings as dividends,
- plans to buy back up to 100m shares over two years (5.3% of outstanding shares),
- insurance reporting a segment PBT of S$0.14m in 2HFY24 (2H23 loss of S$5.8m, 1H24 loss of S$6.5m), and
- 14% y-o-y and h-o-h China revenue growth in 2HFY24.
Business updates.
- Read more at SGinvestors.io.
